In vivo evidence for therapeutic properties of cannabidiol (CBD) for alzheimer's disease

Frontiers in Pharmacology

Volumn 8, Issue FEB, 2017, Pages

  Watt, Georgia ^a   Karl, Tim ^a,b  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Alzheimer's disease; Cannabidiol; Therapy; Transgenic mouse model; 9 tetrahydrocannabinol

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CHOLINESTERASE INHIBITOR; ENDOCANNABINOID; GLIAL FIBRILLARY ACIDIC PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMANTINE; NEUROTROPHIN; PROTEIN P50; PROTEIN P56;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTROCYTE; CELL VIABILITY; COGNITIVE DEFECT; DIARRHEA; DIZZINESS; ENVIRONMENTAL FACTOR; FATIGUE; FATTY ACID SYNTHESIS; GLIA CELL; GLIOSIS; HALLUCINATION; HUMAN; IN VIVO STUDY; NAUSEA; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; UBIQUITINATION; VOMITING;

EID: 85014167897     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00020     Document Type: Short Survey

References (63)

1. Ahmed, A., van der Marck, M., van den Elsen, G., and Olde Rikkert, M. (2015). Cannabinoids in late-onset Alzheimer's disease. Clin. Pharmacol. Ther. 97, 597-606. doi: 10.1002/cpt.117
2. Alzheimer's Association (2015). 2015 Alzheimer's disease facts and figures. Alzheimer's Demen. 11, 332-384. doi: 10.1016/j.jalz.2015.02.003
3. Aso, E., Andrés-Benito, P., and Ferrer, I. (2016). Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model. J. Alzheimers Dis. 54, 903-912. doi: 10.3233/iad-160533
4. Aso, E., and Ferrer, I. (2015). Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front. Pharmacol. 5:37. doi: 10.3389/fphar.2014.00037
5. Aso, E., Sánchez-Pla, A., Vegas-Lozano, E., Maldonado, R., and Ferrer, I. (2015). Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J. Alzheimer's Dis. 43, 977-991. doi: 10.3233/JAD-141014
6. Bedse, G., Romano, A., Lavecchia, A. M., Cassano, T., and Gaetani, S. (2015). The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease. J. Alzheimer's Dis. 43, 1115-1136. doi: 10.3233/JAD-141635
7. Bergamaschi, M. M., Queiroz, R. H. C., Zuardi, A. W., and Crippa, A. S. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr. Drug Saf. 6, 237-249. doi: 10.2174/157488611798280924
8. Bettens, K., Sleegers, K., and Van Broeckhoven, C. (2013). Genetic insights in Alzheimer's disease. Lancet Neurol. 12, 92-104. doi: 10.1016/S1474-4422(12)70259-4
9. Bilkei-Gorzo, A. (2012). The endocannabinoid system in normal and pathological brain ageing. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 367, 3326-3341. doi: 10.1098/rstb.2011.0388
10. Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845-852. doi: 10.1038/sj.bjp.0704327
11. Casarejos, M. J., Perucho, J., Gomez, A., Mu-oz, M. P., Fernandez-Estevez, M., Sagredo, O., et al. (2013). Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J. Alzheimer's Dis. 35, 525-539. doi: 10.3233/JAD-130050.
12. Chapman, P. F., Falinska, A. M., Knevett, S. G., and Ramsay, M. F. (2001). Genes, models and Alzheimer's disease. Trends. Genet. 17, 254-261. doi: 10.1016/S0168-9525(01)02285-5
13. Cheng, D., Low, J. K., Logge, W., Garner, B., and Karl, T. (2014). Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1γ E9 mice. Psychopharmacology (Berl). 231, 3009-3017. doi: 10.1007/s00213-014-3478-5
14. Cheng, D., Spiro, A. S., Jenner, A. M., Garner, B., and Karl, T. (2014). Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. J. Alzheimer's Dis. 42, 1383-1396. doi: 10.3233/JAD-140921
15. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., et al. (2010). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32, 451-459. doi: 10.1179/016164109X12590518685660
16. Di Marzo, V., Stella, N., and Zimmer, A. (2015). Endocannabinoid signalling and the deteriorating brain. Nat. Rev. Neurosci. 16, 30-42. doi: 10.1038/nrn3876
17. Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A. A., and Iuvone, T. (2006). The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. J. Mol. Med. 84, 253-258. doi: 10.1007/s00109-005-0025-1
18. Esposito, G., De Filippis, D., Maiuri, M. C., De Stefano, D., Carnuccio, R., and Iuvone, T. (2006). Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-κB involvement. Neurosci. Lett. 399, 91-95. doi: 10.1016/j.neulet.2006.01.047
19. Esposito, G., Scuderi, C., Savani, C., Steardo, L., Filippis, D., Cottone, P., et al. (2007). Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. Br. J. Pharmacol. 151, 1272-1279. doi: 10.1038/sj.bjp.0707337
20. Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., et al. (2011). Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS ONE 6:e28668. doi: 10.1371/journal.pone.0028668
21. Fadda, P., Robinson, L., Fratta, W., Pertwee, R. G., and Riedel, G. (2004). Differential effects of THC-or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47, 1170-1179. doi: 10.1016/j.neuropharm.2004.08.009
22. Germain, N., Boichot, E., Advenier, C., Berdyshev, E. V., and Lagente, V. (2002). Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-a production by human mononuclear cells. Int. Immunopharmacol. 2, 537-543. doi: 10.1016/S1567-5769(01)00200-4
23. Gotz, J., and Ittner, L. M. (2008). Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 9, 532-544. doi: 10.1038/nrn2420
24. Hamelink, C., Hampson, A., Wink, D. A., Eiden, L. E., and Eskay, R. L. (2005). Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J. Pharmacol. Exp. Ther. 314, 780-788. doi: 10.1124/jpet.105.085779
25. Hampson, A., Grimaldi, M., Axelrod, J., and Wink, D. (1998). Cannabidiol and (-) Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A. 95, 8268-8273. doi: 10.1073/pnas.95.14.8268
26. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi: 10.1126/science.1072994
27. Harvey, B. S., Ohlsson, K. S., Mååg, J. L., Musgrave, I. F., and Smid, S. D. (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology 33, 138-146. doi: 10.1016/j.neuro.2011.12.015
28. Herrmann, N., Li, A., and Lanctôt, K. (2011). Memantine in dementia: a review of the current evidence. Expert Opin. Pharmacother. 12, 787-800. doi: 10.1517/14656566.2011.558006
29. Imbimbo, B. P., and Giardina, G. A. (2011). γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr. Top. Med. Chem. 11, 1555-1570. doi: 10.2174/156802611795860942
30. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A. A. (2004). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J. Neurochem. 89, 134-141. doi: 10.1111/j.1471-4159.2003.02327.x
31. Janefjord, E., Mååg, J. L., Harvey, B. S., and Smid, S. D. (2014). Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell. Mol. Neurobiol. 34, 31-42. doi: 10.1007/s10571-013-9984-x
32. Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., and van den Bussche, H. (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Br. Med. J. 331, 321-327. doi: 10.1136/bmj.331.7512.321
33. Kamboh, M. I. (2004). Molecular genetics of late-onset Alzheimer's disease. Ann. Hum. Genet. 68, 381-404. doi: 10.1046/j.1529-8817.2004.00110.x
34. Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., et al. (2011). Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl). 218, 443-457. doi: 10.1007/s00213-011-2342-0
35. Leweke, F., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C., Hoyer, C., et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2:e94. doi: 10.1038/tp.2012.15
36. Lunn, C. A., Fine, J. S., Rojas-Triana, A., Jackson, J. V., Fan, X., Kung, T. T., et al. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. 316, 780-788. doi: 10.1124/jpet.105.093500
37. Maccioni, R. B., Rojo, L. E., Fernandez, J. A., and Kuljis, R. O. (2009). The role of neuroimmunomodulation in Alzheimer's disease. Ann. N. Y. Acad. Sci. 1153, 240-246. doi: 10.1111/j.1749-6632.2008.03972.x
38. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., and Kivipelto, M. (2010). Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702-716. doi: 10.1016/S1474-4422(10)70119-8
39. Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., and Behl, C. (2002). Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80, 448-456. doi: 10.1046/j.0022-3042.2001.00716.x
40. Martín-Moreno, A. M., Reigada, D., Ramírez, B. G., Mechoulam, R., Innamorato, N., Cuadrado, A., et al. (2011). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol. Pharmacol. 79, 964-973. doi: 10.1124/mol.111.071290
41. McGeer, P. L., Rogers, J., and McGeer, E. G. (2006). Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J. Alzheimers Dis. 9, 271-276.
42. McHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., et al. (2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 11:44. doi: 10.1186/1471-2202-11-44
43. Mukhopadhyay, P., Rajesh, M., Horváth, B., Bátkai, S., Park, O., Tanchian, G., et al. (2011). Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic. Biol. Med. 50, 1368-1381. doi: 10.1016/j.freeradbiomed.2011.02.021
44. Mullane, K., and Williams, M. (2013). Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem. Pharmacol. 85, 289-305. doi: 10.1016/j.bcp.2012.11.014
45. Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., et al. (2011). A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols*(Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18, 1122-1131. doi: 10.1111/j.1468-1331.2010.03328.x
46. Pertwee, R. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabino, cannabidiol and Δ9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215. doi: 10.1038/sj.bjp.0707442
47. Pertwee, R. G., Ross, R. A., Craib, S. J., and Thomas, A. (2002). (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur. J. Pharmacol. 456, 99-106. doi: 10.1016/S0014-2999(02)02624-9
48. Petitet, F., Jeantaud, B., Reibaud, M., Imperato, A., and Dubroeucq, M. C. (1998). Complex pharmacology of natural cannabivoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63, PL1-PL6. doi: 10.1016/S0024-3205(98)00238-0
49. Pomara, N., Singh, R., Deptula, D., Chou, J. C., Schwartz, M. B., and LeWitt, P. A. (1992). Glutamate and other CSF amino acids in Alzheimer's disease. Am. J. Psychiatry 149, 251-254. doi: 10.1176/ajp.149.2.251
50. Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., and Maccioni, R. B. (2008). Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch. Med. Res. 39, 1-16. doi: 10.1016/j.arcmed.2007.10.001
51. Russo, E. B., Burnett, A., Hall, B., and Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30, 1037-1043. doi: 10.1007/s11064-005-6978-1
52. Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N. O., Leonova, J., et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092-1101. doi: 10.1038/sj.bjp.0707460
53. Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., and Drago, F. (2012). New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol. 73, 504-517. doi: 10.1111/j.1365-2125.2011.04134.x
54. Schenk, D., Basi, G. S., and Pangalos, M. N. (2012). Treatment strategies targeting amyloid β-protein. Cold Spring Harb. Perspect. Med. 2:a006387. doi: 10.1101/cshperspect.a006387
55. Schliebs, R., and Arendt, T. (2011). The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 221, 555-563. doi: 10.1016/j.bbr.2010.11.058
56. Scuderi, C., Steardo, L., and Esposito, G. (2014). Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of β amyloid expression in SHSY5YAPP+ cells through PPARγ involvement. Phytother. Res. 28, 1007-1013. doi: 10.1002/ptr.5095
57. Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., et al. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537, 50-56. doi: 10.1038/nature19323
58. Thomas, A., Baillie, G., Phillips, A., Razdan, R., Ross, R., and Pertwee, R. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150, 613-623. doi: 10.1038/sj.bjp.0707133
59. Thomas, B. F., Gilliam, A. F., Burch, D. F., Roche, M. J., and Seltzman, H. H. (1998). Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharmacol. Exper. Ther. 285, 285-292.
60. Van der Schyf, C. J., and Geldenhuys, W. J. (2011). Multimodal drugs and their future for Alzheimer's and Parkinson's disease. Int. Rev. Neurobiol. 100, 107-125. doi: 10.1016/B978-0-12-386467-3.00006-6
61. Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., et al. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23, 1398-1405.
62. Walter, L., and Stella, N. (2004). Cannabinoids and neuroinflammation. Br. J. Pharmacol. 141, 775-785. doi: 10.1038/sj.bjp.0705667
63. Wisniewski, T., and Goni, F. (2014). Immunotherapy for Alzheimer's disease. Biochem. Pharmacol. 88, 499-507. doi: 10.1016/j.bcp.2013.12.020